Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Elan Board Rejects Royalty Pharma Revised Tender Offer

June 10 (Bloomberg) -- Elan Corp.’s board unanimously rejected Royalty Pharma’s takeover offer days after it was raised to $6.7 billion, the second increase in its attempt to take over the Irish biotechnology company.

The latest offer “continues to grossly undervalue” Elan, the Dublin-based company said in a statement today. The board recommended that shareholders take no action on the offer and that they vote in favor of the four transactions previously announced by Elan when the June 17 shareholder meeting takes place.

Link to Company News:{3519426Z US <Equity> CN <GO>} Link to Company News:{ELN ID <Equity> CN <GO>}

To contact the reporter on this story: Makiko Kitamura in London at

To contact the editor responsible for this story: Kristen Hallam at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.